Belgium-based Cardio3 BioSciences (C3BS) has acquired US-based CorQuest Medical, which develops devices and technologies for cardiac surgery.


Terms of the transaction were not disclosed.

Cardio3 BioSciences CEO Christian Homsy said: "As part of our business strategy of building further on our cardiovascular diseases expertise, we have been actively seeking to acquire technologies that complement our existing medical devices for treating severe heart conditions.

"This invention is truly novel and may solve one of the very significant issues in mitral valve repair for example. Indeed, today, mitral valve repair procedures require a convoluted access to the valve."

CorQuest’s heart access technology comprises multiple instruments, which allows quick and easy trans-thoracic access to the heart, directly into the left atrium.

According to C3BS, insertion of the heart access sheath into a patient’s left atrium will allow the deployment of catheters or other instruments to treat different indications such as mitral valve occlusion defects, when CE marked.

C3BS intends to progress the device through the appropriate clinical and regulatory approval processes, which is currently in the advanced pre-clinical development phase.

The company aims to obtain CE mark approval by the end of 2016, targeting the first indication with the CorQuest technology to repair or replace the mitral valve.

CorQuest technology platform is complementary with the firm’s C-Cath and C-Cure programs.

C3BS’ acquisition of CorQuest includes a line of medical devices and implants targeted at various structural heart diseases including atrial fibrillation and mitral valve diseases, in addition to the heart access technology.

Image: Cardio3 BioSciences has acquired cardiac medical devices and technologies developer CorQuest Medical. Photo: courtesy of dream designs/